V 404

Drug Profile

V 404

Alternative Names: V404; V404 PDS; V404 port delivery system

Latest Information Update: 16 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ForSight VISION4
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Uveitis

Most Recent Events

  • 10 Jan 2017 ForSight VISION4 has been acquired by and merged into Roche
  • 19 Aug 2016 No recent reports on development identified - Phase-I/II for Uveitis in USA (Intraocular)
  • 04 Mar 2015 ForSight VISION4 terminates phase I/II clinical trial in Uveitis in USA (NCT02125266)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top